Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry

Cynthia Nourisson, Martin Soubrier, Aurélien Mulliez, Athan Baillet, Thomas Bardin, Alain Cantagrel, Bernard Combe, Maxime Dougados, René-Marc Flipo, Thierry Schaeverbeke, Jean Sibilia, Olivier Vittecoq, Philippe Ravaud, Jacques-Eric Gottenberg, Xavier Mariette, Anne Tournadre

ABSTRACT

Objective The impact of gender on the response and tolerance to abatacept was assessed in a large prospective cohort during 2 years of follow-up.

Methods From the 1017 patients included in the Orencia and Rheumatoid Arthritis registry, disease activity was assessed at baseline, 6, 12 and 24 months. The relationship between the European League Against Rheumatism (EULAR) response, Disease Activity Score 28 (DAS28) remission, rate of adverse events and gender was explored in multivariate analysis.

Results 990 patients, 79.3% female, with at least one follow-up visit were analysed. At baseline, women had longer disease duration, higher disease activity and more often received antitumour necrosis factor (TNF) drugs. The remission was not different between men and women during the follow-up after adjustment on age, disease duration and activity, rheumatoid factor and anti-cyclic citrullinated peptide (CCP) positivity, and current disease-modifying antirheumatic drugs (DMARDs), previous TNF blockers and corticosteroids use. The proportion of men and women achieving EULAR good-or-moderate response at any endpoints was similar (52.4% vs 55.5%), as well as time to achieving EULAR response (5.4±4.9 vs 5.6±5.2 months).

Moderate EULAR response was more frequent in women at 6 months (OR=1.80, p=0.02) but was no longer significant at 12 or 24 months. During the follow-up, the DAS28, the tender joint count score and the patient global assessment remained higher in women (p=0.001, 0.04 and 0.06, respectively). Drug retention and safety were comparable.

Conclusion In this large daily practice cohort of established rheumatoid arthritis treated with abatacept, women achieved similar remission and EULAR response than men despite higher disease activity and tender joint count during the treatment course.

INTRODUCTION

Sex and gender differences in rheumatoid arthritis (RA) are first supported by epidemiological evidence, women being affected three times more often than men, but are also reported in RA outcomes as well as in treatment responses. Biological factors, particularly hormones, may be the reason for the sex differences, with an inductive role of female hormones at the onset of the disease and a protective role of androgens. In addition, gender in a complex interplay with sex must be considered to explore differences in disease manifestations, outcome and management. Separating the influence of sex and gender is difficult as sex can modify behaviours, and gender behaviour can impact biological factors and thereby health. Gender differences associated with behaviour or lifestyle may include...
environmental or nutritional factors, and differences in the use of drugs.\textsuperscript{2,3} More severe disease, worse functional outcome and less sustained remission in women\textsuperscript{4–8} raise the issue of gender-sensitive treatment strategies. Data from the national biologics registers are useful to investigate differences between men and women in treatment response. Treatment response to tumour necrosis factor (TNF) blockers was found lower in women in the British and Danish registers.\textsuperscript{4,9} Conflicting data with rituximab have been obtained from the French and British registries.\textsuperscript{10,11} In patients from The Danish Registry for Biologic Therapies (DANBIO) registry treated with abatacept or tocilizumab,\textsuperscript{12} the sex was not a predictive factor for remission or drug survival, and no data beyond 6 months of follow-up have been published with abatacept in the French register.\textsuperscript{13}

The Orencia and Rheumatoid Arthritis (ORA) is a French national registry founded in 2008 by the ‘Club Rhumatismes Inflammatoires’ and the ‘French Society of Rheumatology’ that records efficacy and safety data on patients with RA treated with abatacept.\textsuperscript{13} Therefore, from this large prospective observational cohort of patients with RA treated with abatacept in ‘real life’, we aimed to assess the impact of gender on the response and tolerance to treatment during 2 years of follow-up.

### Methods

The ORA registry is a French nationwide, multicentre, prospective cohort study investigating the tolerance and efficacy of intravenous abatacept in patients treated for RA.\textsuperscript{13} The methodology of the registry has been previously reported.\textsuperscript{13} The registry was approved by the French authorities (‘Comité Consultatif sur le Traitement de l’information en matière de Recherche dans le domaine de la Santé’ and ‘Commission Nationale de l’Informatique et des Libertés’). All the patients gave informed consent for participation. This registry recruited adult patients receiving abatacept for RA from 82 centres between 2008 and 2010. Centres were informed that including patients in this observational registry would not interfere with their current practice or involve additional laboratory testing. Characteristics of the patients (age, gender, disease duration, swollen joint count (SJC), tender joint count (TJC), Visual Analogue Scale for patients’ global assessment), clinical Disease Activity Scores 28 (DAS28-ESR), biological parameters anti-cyclic citrullinated peptide (anti-CCP), rheumatoid factor, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP)), current DMARDs, previous TNF blockers, steroid use, and infections were recorded at baseline (at the time

### Table 1  Baseline characteristics of the 990 patients analysed

| Characteristics                  | Missing data (%) | Men n=206  | Women n=784 | p Value |
|----------------------------------|------------------|-----------|-------------|---------|
| **Age (years), mean±SD**         | 0 (0)            | 58.7±11.6 | 57.4±14.2   | 0.20    |
| **Weight (kg)**                  | 203 (20.5)       | 80.6±15.3 | 67.2±34.4   | <0.001  |
| **Working, n (%)**               | 231 (23.3)       | 54 (30.7) | 140 (24)    | 0.03    |
| **Smoking, n (%)**               | 14 (1.4)         | 35 (17.0) | 65 (8.4)    | <0.001  |
| **Disease duration (years), median [IQR]** | 4 (0.4)         | 15 [9–21] | 17 [11–24] | <0.001  |
| **Disease Activity Score 28, mean±SD** | 163 (16.5)     | 5±1.3     | 5.4±1.3     | <0.001  |
| **Rheumatoid factor positivity, n (%)** | 169 (17.1)     | 131 (77.1)| 453 (69.6) | 0.06    |
| **Anti-CCP antibodies, n (%)**   | 266 (26.9)       | 117 (75.5)| 389 (68.4) | 0.09    |
| **Extra-articular manifestations, n (%)** | 21 (2.1)        | 30 (14.7) | 75 (9.8)    | 0.04    |
| **CRP (mg/L), median [IQR]**     | 252 (25.5)       | 15 [5–32] | 13.4 [5–30] | 0.51    |
| **ESR, median [IQR]**            | 322 (32.5)       | 24 [13–42] | 29 [15–52] | 0.07    |
| **Cardiovascular diseases, n (%)** | 18 (1.8)         | 71 (35)   | 138 (18)    | <0.001  |
| **Diabetes, n (%)**              | 55 (5.5)         | 35 (18.6) | 75 (10)     | 0.001   |
| **Lung diseases, n (%)**         | 12 (1.2)         | 52 (25.2) | 163 (21.1) | 0.20    |
| **Kidney diseases, n (%)**       | 13 (1.3)         | 18 (8.9)  | 41 (5.3)    | 0.07    |
| **Cancers**                      | 7 (0.7)          | 13 (6.3)  | 45 (5.8)    | 0.74    |
| **Current DMARD, n (%)**         | 4 (0.4)          | 140 (68.6)| 501 (64.9)  | 0.32    |
| **Current MTX, n (%)**           | 4 (0.4)          | 108 (77.1)| 380 (75.8)  | 0.77    |
| **Current steroids, n (%)**      | 18 (1.8)         | 159 (77.9)| 580 (75.5)  | 0.47    |
| **Prednisone dose, mg/kg/day, mean±SD** | 17 (2.3)        | 0.17±0.15 | 0.17±0.13   | 0.10    |
| **Prior TNF inhibitors, n (%)**  | 1 (0.1)          | 172 (83.5)| 693 (88.5)  | 0.05    |

CCP, cyclic citrullinated peptid e; CRP, C reactive protein; DMARD, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; MTX, methotrexate; TNF, tumour necrosis factor.
of the patient’s first exposure to the drug) and then every 6 months. The efficacy of abatacept was assessed by the remission rate, defined as a DAS28-ESR <2.6 and the percentage of European League Against Rheumatism (EULAR) responses (good, moderate, good or moderate versus non-response) according to the EULAR criteria during the follow-up (6, 12 and 24 months).

**STATISTICAL ANALYSIS**

The statistical analysis was performed using Stata V.12 software. The primary outcome was the EULAR good-or-moderate response; exploratory analyses were performed for remission and retention rates. Tests were two-sided and a p value <5% was considered significant. The baseline characteristics of the study population were reported as mean (SD) or median and IQR according to statistical distribution for quantitative variables and as frequencies (associated percentages) for categorical parameters. Comparisons of these baseline characteristics between male and female patients were analysed using the $\chi^2$ (or Fisher’s exact test when necessary) for categorical variables and Student’s t-test (or Kruskal-Wallis test when normality assessed by the Shapiro-Wilk test was not verified). The relationship between the EULAR response, DAS28 remission, rate of adverse events (at 6, 12 and 24 months) and gender was explored in multivariate analysis using a random-effects model taking subject as random effect, with adjustment on age, disease duration, rheumatoid factor (RF) or anti-CCP positivity, current DMARDs or previous tumour necrosis factor blockers and corticoids use, and rheumatoid arthritis activity. Interaction between gender and time was tested. To avoid bias due to loss to follow-up, treatment discontinuation for inefficacy was considered as a non-response/non-remission for the visit and during the follow-up, and missing data (at 6, 12 and 24 months) were imputed using last observation carry forward. Results were expressed as the OR with 95% CI. We carried out analyses of treatment discontinuation (for adverse event and inefficacy) using survival methods to take into account the time to event. Longitudinal changes in the DAS score and its components were also analysed by random effects, taking subject as random

| Follow-up | Male | Female | OR [CI 95%], p value (univariate analysis) | OR [CI 95%], p value (multivariate analysis*) |
|-----------|------|--------|------------------------------------------|---------------------------------------------|
| 6 months  | n=179| n=683  |                                          |                                             |
| Remission (%) | 33 (18.4) | 72 (10.5) | 0.52 [0.33 to 0.82], p=0.005               | 0.62 [0.34 to 1.15], p=0.13                 |
| EULAR response (%) | n=155 | n=624 |                                          |                                             |
| Without response | 85 (54.8) | 297 (47.6) | 1                                        | 1                                           |
| Moderate response | 39 (25.2) | 231 (37) | 1.70 [1.12 to 2.57], p=0.01               | 1.80 [1.08 to 3.00], p=0.02                 |
| Good response   | 31 (20.0) | 96 (15.4) | 0.89 [0.55 to 1.42], p=0.62               | 1.13 [0.62 to 2.06], p=0.68                 |
| Good or moderate | 70 (45.2) | 327 (52.4) | 1.34 [0.94 to 1.90], p=0.11               | 1.50 [0.97 to 2.32], p=0.07                 |
| 12 months      | n=191| n=722  |                                          |                                             |
| Remission (%)  | 35 (18.3) | 81 (11.2) | 0.56 [0.37 to 0.87], p=0.009              | 0.80 [0.42 to 1.53], p=0.51                 |
| EULAR response (%) | n=169 | n=661 |                                          |                                             |
| Without response | 98 (58.0) | 375 (56.7) | 1                                        | 1                                           |
| Moderate response | 41 (24.3) | 189 (28.6) | 1.20 [0.80 to 1.80], p=0.37               | 1.21 [0.72 to 2.04], p=0.46                 |
| Good response   | 30 (17.7) | 97 (14.7) | 0.84 [0.53 to 1.35], p=0.48               | 0.85 [0.47 to 1.54], p=0.60                 |
| Good or moderate | 71 (42.0) | 286 (43.3) | 1.05 [0.75 to 1.48], p=0.77               | 0.81 [0.46 to 1.42], p=0.47                 |
| 24 months      | n=197| n=741  |                                          |                                             |
| Remission (%)  | 39 (19.8) | 75 (10.1) | 0.46 [0.30 to 0.70], p<0.001              | 0.69 [0.37 to 1.28], p=0.24                 |
| EULAR response (%) | n=180 | n=685 |                                          |                                             |
| Without response | 114 (63.3) | 449 (65.6) | 1                                        | 1                                           |
| Moderate response | 31 (17.2) | 147 (21.5) | 1.20 [0.78 to 1.87], p=0.41               | 1.12 [0.65 to 1.90], p=0.69                 |
| Good response   | 35 (19.4) | 89 (13.0) | 0.65 [0.42 to 1.00], p=0.052              | 0.77 [0.43 to 1.37], p=0.37                 |
| Good or moderate | 66 (36.7) | 236 (34.5) | 0.91 [0.65 to 1.28], p=0.58               | 0.85 [0.42 to 1.71], p=0.64                 |

*After adjustment on age, disease duration, RF or anti-CCP positivity, current DMARDs or previous tumour necrosis factor blockers and corticoids use, and rheumatoid arthritis activity.

EULAR, European League Against Rheumatism.
RESULTS

Gender differences at baseline

Baseline comparisons between men and women are presented table 1. Among the 1017 patients enrolled in the ORA registry, 990 had at least one follow-up visit and were included in the analysis. Seven hundred and eighty-four were women (79.2%) with a mean age of 57.4±14.2 years. Women had longer disease duration (p<0.001) and higher disease activity (p<0.001) at baseline. Rheumatoid factor and anti-CCP positivity were observed in a similar way between women and men. Cardiovascular risk factors, smoking and extra-articular manifestations were more frequent in men. No differences for the use of DMARDs or steroids were observed, but women more often previously received TNF blockers (p=0.05).

Efficacy of abatacept

Although men appeared to have better remission rate in univariate analyses, the DAS28 remission rate did not significantly differ between men and women during the follow-up after adjustment on age, disease duration, rheumatoid factor or anti-CCP positivity, current DMARDs, previous TNF blockers and glucocorticoids use, and disease activity (table 2).

The proportion of patients achieving EULAR good-or-moderate response at any endpoints did not differ between men and women (52.4% vs 55.5%, p=0.42). Time to achieving EULAR good-or-moderate response was similar in women and men (5.4±4.9 vs 5.6±5.2 months, p=0.76).
Moderate EULAR response was more frequent in women at 6 months but was no longer significant at 12 or 24 months (table 2). During the follow-up the DAS28-ESR (p=0.001), the TJC (p=0.04) and the patient global assessment (p=0.06) remained higher in women, whereas SJC and ESR did not differ between men and women at any endpoints (figure 1).

**Drug retention rate and safety**

Treatment with abatacept was maintained in 86.9%, 72.5% and 52.8% of men and 91.1%, 72.8% and 55.8% of women at the 6-month, 12-month and 24-month follow-up visits, respectively (figure 2). During the follow-up, 73.1% of women and 69.4% of men stopped the treatment at least one time (p=0.3), because of inefficacy in 69.1% of men and 64% of women (p=0.24), and adverse events in 14% and 15%, respectively (p=0.76). Serious infections occurred in the same way in men and women (5.5 vs 4.2/100 patient-years, p=0.3) during the 2 years of follow-up. Cancer occurred in 10 men and 17 women (2.4 vs 1.1/100 patient-years, p=0.06) and death in 4 men and 1 woman.

**DISCUSSION**

In this large study of patients with RA treated in real life with abatacept, we were not able to demonstrate any differences for remission rates or EULAR response during the 2 years of follow-up between men and women, except for the moderate EULAR response being better in women after 6 months of treatment. However, differences in disease expression between men and women were observed. Despite similar improvement in disease activity score with treatment, women had greater absolute activity at baseline and during follow-up, which may be explained by higher TJC. Thus, the only DAS28 component that significantly differed during the longitudinal analysis was the TJC. Previous studies in RA have shown higher disease activity in women as measured by the DAS28, TJC score and patient global assessment,¹⁵-¹⁷ contrasting with similar radiographical progression.¹⁴ Gender differences in pain perception and assessment reported in RA as well as in spondyloarthritis¹⁸,¹⁹ may explain this dissociation.

Gender was further analysed as a predictor of remission in several studies. Remission rates were found lower in women whether patients received conventional DMARDs or biologics.¹⁰ ²⁰-²⁵ Thus, in an observational study including 142 patients with recent-onset RA treated with DMARDs, remission was more frequently achieved in men than in women after 5 years of follow-up.²⁰ The Swedish Better Anti-Rheumatic FarmaCoTherapy (BARFOT) cohort including 698 patients with early RA reported similar findings after 2 and 5 years of treatment, mainly with conventional DMARDs.⁸ ¹⁵ In long-standing RA from the British Society for Rheumatology Biologics Register, remission with TNF blockers was achieved less frequently for women, but EULAR response did not differ.⁷ Similar results were observed with rituximab in the French registry after 2 years of follow-up,³⁰ and less improvement in DAS28 after 6 months of follow-up was noted in the British registry.¹¹ Interestingly, the gender difference for the response to biologics seems to be focused on the remission as defined by the absolute DAS28 score and also depends on the disease duration. Poorer response with TNF blockers was observed in women only in early RA during the 4 years of follow-up, whereas no difference was observed after adjustment on disease duration and disease activity in established RA of more than 2 years’ duration.⁴ As observed with TNF blockers, we noted that the gender difference for the remission rates in established RA treated with abatacept did not persist when adjusted for disease activity and disease duration higher in women.

Several limitations of our study should be noted. First, we could not analyse the severity of the disease, notably the functional impairment and disability status as the Health Assessment Questionnaire (HAQ) and radiographs were not available in the ORA registry. As it is an observational study reflecting routine clinical practice, missing data for some variables is another possible limitation of our analysis.

In conclusion, in this large daily practice cohort of patients with established RA treated with abatacept, women achieved similar remission and EULAR response than men despite higher disease activity and TJC score during the treatment course. Drug retention rate and safety were comparable between the two genders. Gender differences for treatment response and remission should now be focused on in early RA.

**Author affiliations**

Rheumatology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France
²UNI-UMR 1019, INRA and University of Auvergne, Clermont-Ferrand, France
³Biostatistic Unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France
⁴Rheumatology Department, CHU Grenoble Sud Hospital, Grenoble, France
⁵Rheumatology Department, Lapeyronie Hospital, Montpellier University, Montpellier, France
⁶Rheumatology Department, Hospital Lariboisiere, Paris, France
⁷Rheumatology Department, Purpan Hospital, Toulouse, France
⁸Rheumatology Department, Lapeyronie Hospital, Montpellier University, Montpellier, France
⁹Rheumatology B, Cochin Hospital, René Descartes University INSERM (U1153), Paris, France
¹⁰Rheumatology Department, CHU Lille, Lille, France
¹¹Rheumatology Department, CHU Bordeaux, Bordeaux, France
¹²Rheumatology Department, CHU Strasbourg, Strasbourg, France
¹³Rheumatology Department, Rouen University Hospital, Inserm U905, CIC/CRB 1404, Institute for Research and Innovation in Biomedicine (IRBiB), University of Rouen, 76031, Rouen, France
¹⁴Centre d’Épidémiologie Clinique, Hotel Dieu, Assistance Publique, Hopitaux de Paris, Paris, France
¹⁵Rheumatology Department, Université Paris-Sud, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, INSERM U1118, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France

**Acknowledgements** We thank EuraPix Pharma for the help of their clinical research associates and all the investigators of the ORA registry, the French Society of Rheumatology, E Bocard (BMS), the 14 research study nurses (A Bourgeois, E Bracheno, F Carmet, MH Da Silva, S Delmas, D Guenement, R Lefebvre, C Lehning, N Minot, FMA Ouattara, V Pinosa, M Reau, H Thibault and E Wallet), and L Dongno and V Martin (EuraPix Pharma) for their contributions. This work was presented at conferences and published as a conference abstract: EULAR 2015, French Congress of Rheumatology 2015.

**Funding** No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.
Competing interests None declared.

Patient consent Obtained.

Ethics approval The registry was approved by the French authorities ('Comité Consultatif sur le Traitement de l’information en matière de Recherche dans le domaine de la Santé’ (CCTIRS) and ‘Commission Nationale de l’Informatique et des Libertés’ (CNIL)). The ethical committees of all participating centres approved the ORA registry.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
1. Kvien TK, Uhlig T, Ødegård S, et al. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 2006;1069:212–22.
2. Da Silva JA, Larbre JP, Spector TD, et al. Protective effect of androgens against inflammation induced cartilage degradation in male rodents. Ann Rheum Dis 1993;52:285–91.
3. Ishizuka M, Hatori M, Suzuki T, et al. Sex steroid receptors in rheumatoid arthritis. Clin Sci 2004;106:293–300.
4. Jawaher D, Olsen J, Hetland ML. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis -- results from the DANBIO registry. J Rheumatol 2012;39:46–53.
5. Lee J, Mason R, Martin L, et al. Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study. Rheumatol Int 2014;34:1449–53.
6. Jawaher D, Maranian P, Park G, et al. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 2010;37:2475–85.
7. Kuiper S, van Gestel AM, Swinkels HL, et al. Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J Rheumatol 2001;28:1809–16.
8. Tengstrand B, Ahlmén M, Hafström I. The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J Rheumatol 2004;31:214–22.
9. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558–65.
10. Couderc M, Gottenberg JE, Mariette X, et al. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. Rheumatology 2014;53:1788–93.
11. Soliman MM, Hyrich KL, Lunt M, et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012;39:240–6.
12. Leffers HC, Ostergaard M, Glintborg B, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70:1216–22.
13. Gottenberg JE, Raouadi P, Cantagrel A, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Ocrecia and Rheumatoid Arthritis’ registry. Ann Rheum Dis 2012;71:1815–9.
14. Mariette X, Gottenberg JE, Raouadi P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology 2011;50:222–9.
15. Leeb BF, Haindl PM, Makrari A, et al. Disease activity score-28 values differ considerably depending on patient’s pain perception and sex. J Rheumatol 2007;34:2382–7.
16. Ahlmén M, Svensson B, Albertsson K, et al. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. Ann Rheum Dis 2010;69:230–3.
17. Arkema EV, Neovius M, Joelsson JK, et al. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study. Ann Rheum Dis 2012;71:1203–6.
18. Barnabe C, Bessette L, Flanagan C, et al. Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis. J Rheumatol 2012;39:1221–30.
19. Tournadre A, Pereira B, Lhoste A, et al. Differences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohort. Arthritis Care Res 2013;65:1482–9.
20. Möttönen T, Paimela L, Leirisalo-Repo M, et al. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998;57:533–9.
21. Jayakumar K, Norton S, Dixey J, et al. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDs. Rheumatology 2012;51:169–75.
22. Forslind K, Hafström I, Ahlmén M, et al. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007;66:46–52.
23. Jawaher D, Messing S, Reed G, et al. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of north america cohort of rheumatoid arthritis patients. Arthritis Care Res 2012;64:1811–8.